[go: up one dir, main page]

MA33642B1 - Composés chimiques - Google Patents

Composés chimiques

Info

Publication number
MA33642B1
MA33642B1 MA34737A MA34737A MA33642B1 MA 33642 B1 MA33642 B1 MA 33642B1 MA 34737 A MA34737 A MA 34737A MA 34737 A MA34737 A MA 34737A MA 33642 B1 MA33642 B1 MA 33642B1
Authority
MA
Morocco
Prior art keywords
compounds
chemical compounds
salts
relates
administration
Prior art date
Application number
MA34737A
Other languages
Arabic (ar)
English (en)
Inventor
Pingyun Chen
Ricky Couch
Maosheng Duan
Richard Martin Grimes
Wieslaw Mieczyslaw Kazmierski
Beth Adams Norton
Matthew Tallant
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33642(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA33642B1 publication Critical patent/MA33642B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur des composés de Formule III. L'invention porte également sur des sels des composés, sur une composition pharmaceutique comprenant les composés ou sels et sur des procédés de traitement d'une infection par le VHC par administration des composés ou sels.
MA34737A 2009-09-04 2012-04-02 Composés chimiques MA33642B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23985509P 2009-09-04 2009-09-04
US29732410P 2010-01-22 2010-01-22
US34876710P 2010-05-27 2010-05-27
PCT/US2010/046782 WO2011028596A1 (fr) 2009-09-04 2010-08-26 Composés chimiques

Publications (1)

Publication Number Publication Date
MA33642B1 true MA33642B1 (fr) 2012-10-01

Family

ID=43649589

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34737A MA33642B1 (fr) 2009-09-04 2012-04-02 Composés chimiques

Country Status (22)

Country Link
US (6) US8344155B2 (fr)
EP (2) EP2473056A4 (fr)
JP (1) JP5795316B2 (fr)
KR (1) KR20120076343A (fr)
CN (1) CN102480971B (fr)
AR (1) AR078152A1 (fr)
AU (1) AU2010289762B2 (fr)
BR (1) BR112012003578A8 (fr)
CA (1) CA2771327A1 (fr)
CL (1) CL2012000573A1 (fr)
CO (1) CO6511251A2 (fr)
CR (1) CR20120104A (fr)
DO (1) DOP2012000045A (fr)
EA (1) EA201290089A1 (fr)
IL (1) IL217800A0 (fr)
MA (1) MA33642B1 (fr)
MX (1) MX2012002759A (fr)
NZ (1) NZ597982A (fr)
PE (1) PE20120993A1 (fr)
SG (1) SG178952A1 (fr)
TW (1) TW201121974A (fr)
WO (1) WO2011028596A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
CA2740193A1 (fr) 2008-12-23 2010-07-01 Abbott Laboratories Composes antiviraux
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (fr) 2009-04-15 2010-10-21 Abbott Laboratories Composés antiviraux
PE20120509A1 (es) 2009-05-13 2012-05-09 Gilead Sciences Inc Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PL2455376T3 (pl) 2009-06-11 2015-06-30 Abbvie Bahamas Ltd Związki heterocykliczne jako inhibitory wirusa zapalenia wątroby typu C (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2454254A2 (fr) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Analogues du benzimidazole pour le traitement ou la prévention des infections à flavivirus
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011091417A1 (fr) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011109037A1 (fr) 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la réplication du vhc
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011127350A1 (fr) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
EP2575819A4 (fr) * 2010-06-04 2013-11-27 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012021704A1 (fr) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
WO2013025975A1 (fr) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Traitements combinés pour l'hépatite c
SG2014010490A (en) * 2011-08-24 2014-04-28 Glaxosmithkline Llc Combination treatments for hepatitis c
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US9212168B2 (en) 2011-11-03 2015-12-15 Theravance Biopharma R&D Ip, Llc Hepatitis C virus inhibitors
AP2013006877A0 (en) * 2011-11-16 2013-05-31 Gilead Sciences Inc Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) * 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2850075T (pt) 2012-04-25 2017-05-02 Theravance Biopharma R&D Ip Llc Compostos de piperazina-piperidina como inibidores do vírus da hepatite c
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN111116563B (zh) * 2013-06-06 2023-07-04 上海爱博医药科技有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021846A1 (fr) * 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c
EP3021845A1 (fr) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Associations comprenant des dérivés de biphényle destinées à être utilisées pour le traitement du virus de l'hépatite c
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
TWI679203B (zh) 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
FR3022262B1 (fr) * 2014-06-12 2016-06-03 Michelin & Cie Cable gomme in situ comprenant une composition de gommage comprenant un inhibiteur de corrosion
CN105646285B (zh) * 2014-12-02 2017-11-24 上海医药工业研究院 一种维兰特罗中间体及其制备方法和应用
US10206706B2 (en) 2015-05-29 2019-02-19 Medtronic Xomed, Inc. Inner tubular member for angled rotary surgical instrument
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105777719A (zh) * 2016-03-29 2016-07-20 安徽联创生物医药股份有限公司 一种达卡他韦的合成方法
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法
KR20230142745A (ko) * 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889145A (en) 1907-03-16 1908-05-26 Jewel Electric Sign Company Electric sign.
US1879057A (en) 1930-04-05 1932-09-27 Freeman M Bray Automobile direction signal
US3931207A (en) 1973-12-14 1976-01-06 Smithkline Corporation Tetramic acid analogs of pulvinic acid
JPS5686723U (fr) 1979-12-07 1981-07-11
US4288672A (en) 1979-12-26 1981-09-08 Texas Instruments Incorporated Illuminated keyboard apparatus
US4493958A (en) 1983-09-28 1985-01-15 Stewart-Warner Corporation Illuminated membrane switch
JPS60252388A (ja) 1984-05-29 1985-12-13 株式会社東芝 表示装置
US4811175A (en) 1986-07-09 1989-03-07 Desmet Gregory L Illuminated switch
FI88345C (fi) 1991-01-29 1993-04-26 Nokia Mobile Phones Ltd Belyst tastatur
US5128842A (en) 1991-06-03 1992-07-07 Sunarrow Co., Inc. Uniform illumination plate
US5432684A (en) 1994-01-11 1995-07-11 Delco Electronics Corp. Process for manufacturing painted backlit displays having uniform backlighting intensity
ATE272062T1 (de) 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
US5911317A (en) 1997-08-26 1999-06-15 Silitek Corporation Light permeable metal plated rubber key
US6652128B2 (en) 2001-01-31 2003-11-25 Textron Automotive Company, Inc. Backlighting method for an automotive trim panel
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
US6731913B2 (en) 2002-01-30 2004-05-04 Nokia Corporation Elastomeric enclosure
EP1651631A1 (fr) 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Derives de l'imidazole bicycliques diriges contre les flaviviridae
CA2549228C (fr) 2003-12-11 2013-03-19 Abbott Laboratories Composes inhibiteurs de la protease du vih
JP2007529949A (ja) 2004-03-17 2007-10-25 センステック カンパニー，リミテッド 携帯電話用キーパッドの組立体及びそのキーパッドの製造方法
US20090069384A1 (en) 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7683279B2 (en) 2006-02-28 2010-03-23 Hyun Soo Kim Light emitting keypad comprising light guide film and light guide
KR100754587B1 (ko) 2006-03-03 2007-09-05 삼성전자주식회사 전자기기의 키패드 어셈블리
US7600880B2 (en) 2006-06-12 2009-10-13 Motorola, Inc. Device with modal lighting control and method thereof
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2099778A2 (fr) * 2006-11-21 2009-09-16 Smithkline Beecham Corporation Composés amido antiviraux
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
MX2010008650A (es) 2008-02-12 2010-08-30 Bristol Myers Squibb Co Inhibidores de virus de la hepatitis c.
JP2011511841A (ja) 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2715839C (fr) * 2008-02-13 2014-12-09 Bristol-Myers Squibb Company Imidazolyle diphenyle imidazoles inhibitrices du virus de l'hepatite c
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102307589A (zh) 2008-08-28 2012-01-04 沃泰克斯药物股份有限公司 Hcv的基因型分析
US20100130599A1 (en) 2008-10-03 2010-05-27 William Coty CYP2C9*8 Alleles Correlate With Decreased Warfarin Metabolism And Increased Warfarin Sensitivity
ES2435799T3 (es) 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
AU2009322387A1 (en) 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
WO2010091413A1 (fr) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010096462A1 (fr) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Dérivés du diimidazole lié
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010094977A1 (fr) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Nouveaux composés de biphényle utiles pour le traitement de l'hépatite c
CA2753313A1 (fr) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibiteurs du ns5a du vhc
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
EP2408449A4 (fr) 2009-03-18 2012-08-08 Univ Leland Stanford Junior Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
CA2756255A1 (fr) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Inhibiteurs bicycliques du vhc substitues
NZ595410A (en) 2009-03-27 2013-12-20 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
US9150554B2 (en) 2009-03-27 2015-10-06 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (fr) 2009-04-15 2010-10-21 Abbott Laboratories Composés antiviraux
WO2010122162A1 (fr) 2009-04-24 2010-10-28 Tibotec Pharmaceuticals Ethers de diaryle
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
PE20120509A1 (es) 2009-05-13 2012-05-09 Gilead Sciences Inc Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral
CA2762885A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composes antiviraux constitues de trois fractions d'aryle alignees pour traiter des maladies telles que l'hepatite c
EP2435424B1 (fr) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2455376T3 (pl) 2009-06-11 2015-06-30 Abbvie Bahamas Ltd Związki heterocykliczne jako inhibitory wirusa zapalenia wątroby typu C (HCV)
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (fr) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2011004276A1 (fr) 2009-07-06 2011-01-13 Pfizer Limited Inhibiteurs du virus de l’hépatite c
EP2454254A2 (fr) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Analogues du benzimidazole pour le traitement ou la prévention des infections à flavivirus
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110137633A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
SG2014010490A (en) * 2011-08-24 2014-04-28 Glaxosmithkline Llc Combination treatments for hepatitis c

Also Published As

Publication number Publication date
NZ597982A (en) 2013-01-25
AU2010289762A1 (en) 2012-03-01
CN102480971B (zh) 2014-11-26
CA2771327A1 (fr) 2011-03-10
CL2012000573A1 (es) 2012-08-31
US20130072690A1 (en) 2013-03-21
US20160158201A1 (en) 2016-06-09
IL217800A0 (en) 2012-03-29
DOP2012000045A (es) 2012-05-31
CO6511251A2 (es) 2012-08-31
KR20120076343A (ko) 2012-07-09
CR20120104A (es) 2012-05-28
US8344155B2 (en) 2013-01-01
US9814699B2 (en) 2017-11-14
EP2473056A1 (fr) 2012-07-11
TW201121974A (en) 2011-07-01
JP2013503867A (ja) 2013-02-04
US8492554B2 (en) 2013-07-23
US20110152237A1 (en) 2011-06-23
AR078152A1 (es) 2011-10-19
US8853416B2 (en) 2014-10-07
US20130274304A1 (en) 2013-10-17
US20150374668A1 (en) 2015-12-31
BR112012003578A8 (pt) 2018-02-14
EA201290089A1 (ru) 2012-09-28
EP2473056A4 (fr) 2013-02-13
SG178952A1 (en) 2012-04-27
JP5795316B2 (ja) 2015-10-14
PE20120993A1 (es) 2012-08-22
EP3006441A1 (fr) 2016-04-13
AU2010289762B2 (en) 2015-06-11
WO2011028596A1 (fr) 2011-03-10
MX2012002759A (es) 2012-04-30
BR112012003578A2 (pt) 2015-09-08
US9150587B2 (en) 2015-10-06
US20140371455A1 (en) 2014-12-18
CN102480971A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
MA33642B1 (fr) Composés chimiques
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
MA32941B1 (fr) Composes organiques
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
MA32965B1 (fr) Derives de sulfonamides
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
UA108219C2 (uk) Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти)
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA31754B1 (fr) Cis-imidazolines chirales
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
EA201490436A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.
MY158069A (en) Tricyclic compound and pharmaceutical use thereof